Related Experiment Video

Updated: Jul 14, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Defective Jak-Stat activation in renal cell carcinoma is associated with interferon-alpha resistance

Donghao Shang1, Yuting Liu, Noriyuki Ito

  • 1Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.

Cancer Science
|June 19, 2007
PubMed

Insights

Renal cell carcinoma (RCC) resistance to Interferon (IFN)-alpha is linked to low Jak1, Tyk2, and Stat1. Restoring these proteins may improve IFN-alpha treatment effectiveness for RCC.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Metastatic renal cell carcinoma (RCC) shows poor response to chemotherapy.
  • Interferon (IFN)-alpha is a common but often unsatisfactory treatment for RCC.
  • The mechanisms underlying RCC resistance to IFN-alpha are not fully understood.

Purpose of the Study:

  • To assess the susceptibility of RCC cells to IFN-alpha.
  • To elucidate the molecular mechanisms of IFN-alpha resistance in RCC.

Main Methods:

  • Evaluated six RCC cell lines and three IFN-alpha types.
  • Examined expression, activation, and transfection effects of key signaling proteins.
  • Investigated components of the IFN-alpha signaling pathway.

Main Results:

  • RCC resistance correlated with deficient expression of Jak1, Tyk2, and Stat1.
  • Defective Jak-Stat pathway activation was observed in resistant RCC cells.
  • Transfection with Jak1, Tyk2, or Stat1 vectors restored IFN-alpha sensitivity and pathway activation.

Conclusions:

  • IFN-alpha resistance in RCC is primarily associated with the Jak-Stat signaling pathway.
  • Restoring Jak1, Tyk2, or Stat1 expression is a potential strategy to enhance RCC response to IFN-alpha.
  • Targeting the Jak-Stat pathway offers a promising therapeutic approach for RCC treatment.

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...